| Name | Title | Contact Details |
|---|---|---|
Richard Nolan |
Deputy Chief Information Security Officer | Profile |
Dave Clifford |
Head of Technology and AI, BDH Data | Profile |
Pietr Lindahl |
Deputy Chief Information Security Officer | Profile |
Keith Sarbaugh |
Vice President, IT Infrastructure, Architecture and Operations | Profile |
Chris Fahey |
Director of Security Operations | Profile |
Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs
Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.
BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
Second Genome is a clinical stage company with a mission to improve human health by unlocking the full potential of the microbiome. We offer the most robust approach to microbiome drug discovery and development through the deepest understanding of how the microbiome works in human health.
Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…